Similar articles

• Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

  Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
• Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.

  Simões Corrêa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira VDSN. Simões Corrêa Galendi J, et al. Front Endocrinol (Lausanne). 2021 Sep 17;12:732240. doi: 10.3389/fendo.2021.732240. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34603209 Free PMC article.
• Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.

  Varlamov EV, Han AJ, Fleseriu M. Varlamov EV, et al. Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101490. doi: 10.1016/j.beem.2021.101490. Epub 2021 Feb 6. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 33707082 Review.
• Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.

  Dougherty JA, Desai DS, Herrera JB. Dougherty JA, et al. Ann Pharmacother. 2021 Aug;55(8):1050-1060. doi: 10.1177/1060028020968808. Epub 2020 Nov 3. Ann Pharmacother. 2021. PMID: 33143437
• New prospects for drug treatment in Cushing disease.

  Barahona Constanzo MJ, del Pozo Picó C. Barahona Constanzo MJ, et al. Endocrinol Nutr. 2012 Dec;59(10):599-605. doi: 10.1016/j.endonu.2012.07.008. Epub 2012 Oct 1. Endocrinol Nutr. 2012. PMID: 23036936 Review. English, Spanish.